Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Bharat Biotech Intranasal vaccine receives CDSCO nod for booster

    Bharat Biotech International Limited a global leader in vaccine innovation and developer of vaccines for infectious diseases, today announced that iNCOVACC® (BBV154), has received approval from the Central Drugs Standard Control Organisation (CDSCO) under Rcstrictcd Use in Emcrgcncy Situation for ages 18 and above, in India, for heterologous booster doses.

  • Discovery could lead to new drugs to block protein that fuels bowel cancer

    Scientists have revealed the inner workings of a key protein involved in a wide range of cellular processes – potentially paving the way for better and less toxic cancer drugs.

    Using Nobel Prize-winning microscopy techniques, the researchers revealed how the tankyrase protein switches itself on and off by self-assembling into 3D chain-like structures.

  • AI tailors artificial DNA for future drug development

    With the help of artificial intelligence, researchers at Chalmers University of Technology, Sweden, have succeeded in designing synthetic DNA that controls the cells' protein production. The technology can contribute to the development and production of vaccines, drugs for severe diseases, as well as alternative food proteins much faster and at significantly lower costs than today.

  • AstraZeneca Pharma India get CDSCO nod for Dapagliflozin tablets

    AstraZeneca Pharma India has received an import and market permission in Form CT-20 (subsequent new drug approval) from the Central Drugs Standard Control Organisation for Dapagliflozin tablets of 10 mg.

    Through this approval, the Company is permitted to deal in Dapagliflozin (Forxiga®) tablets of 10 mg in additional/expanded indication to reduce the risk of sustained eGFR and kidney disease, cardiovascular death and hospitalization for heart failure in adult with chronic kidney disease at risk of progression with condition.

  • Eli Lilly launches Ramiven in India

    Eli Lilly India has announced the launch of the additional indication for Ramiven (abemaciclib), following approval from The Drug Controller General of India (DCGI) in combination with endocrine therapy for adjuvant treatment in adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node-positive early breast cancer (EBC) at high risk of recurrence.

  • Antitrust case filed against Dr Reddys Labs in US

    Antitrust case filed against Dr Reddys Labs in the US over maintaining a shared monopoly in the sale of brand and generic Revlimid through their respective settlements of patent litigation with other pharmaceutical companies.

    Dr Reddys Lab along with Celgene, Bristol Myers Squibb and several generic pharmaceutical companies, were named as defendants in a complaint filed on November 18, 2022, in the District of New Jersey, USA.

  • Amneal Launches Second Biosimilar of filgrastim-ayow in the US

    Amneal Pharmaceuticals, Inc announced the commercial launch of RELEUKO® (filgrastim-ayow), a biosimilar referencing Neupogen®. RELEUKO® is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy. This product was developed in collaboration with Kashiv Biosciences, LLC located in Chicago, Illinois.

  • Covid-19 : the Spike protein is no longer the only target

    With the continuous emergence of new variants and the risk of new strains of the virus, the development of innovative therapies against SARS-CoV-2 remains a major public health challenge. Currently, the proteins that are on the surface of the virus and/or are involved in its replication are the preferred therapeutic targets, like the Spike protein targeted by vaccines. One of them, the non-structural protein Nsp1, had been little studied until now.

  • Glenmark Pharma settlement agreement with Pfizer for Axitinib Tablets

    Glenmark Pharmaceuticals Inc., USA (Glenmark) and Glenmark Pharmaceuticals Limited have reached a settlement agreement with Pfizer Inc., PF Prism C.V., and PF Prism IMB B.V. (Pfizer) for Axitinib Tablets, 1 mg and 5 mg, the generic version of their Inlyta®1 Tablets, 1 mg and 5 mg.

    Glenmark had previously announced it received tentative approval by the United States Food & Drug Administration (U.S. FDA) for their generic Axitinib Tablets, 1 mg and 5 mg on November 30, 2020.

  • Aurobindo Pharma facility gets Form 483 with 10 observations

    USFDA has issued Form 483 with 10 observations for the Gundlamachnoor facility of Aurobindo Pharma.

    The United States Food and Drug Administration (US FDA) inspected the Company Unit - IX, an intermediate facility situated at Gundlamachnoor Village, Sangareddy District, Telangana, from November 10 to November 18, 2022.

Subscribe to Pharma News

Search this website